Additionally, the 36-month beta value for RAPT is 0.33. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for RAPT is 31.00M and currently, short sellers hold a 9.25% ratio of that float. The average trading volume of RAPT on October 31, 2024 was 260.47K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RAPT) stock’s latest price update
The stock price of RAPT Therapeutics Inc (NASDAQ: RAPT) has jumped by 10.00 compared to previous close of 2.00. Despite this, the company has seen a gain of 27.91% in its stock price over the last five trading days. zacks.com reported 2024-06-14 that Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RAPT’s Market Performance
RAPT’s stock has risen by 27.91% in the past week, with a monthly rise of 18.92% and a quarterly drop of -29.49%. The volatility ratio for the week is 13.47% while the volatility levels for the last 30 days are 11.17% for RAPT Therapeutics Inc The simple moving average for the past 20 days is 18.84% for RAPT’s stock, with a -68.27% simple moving average for the past 200 days.
Analysts’ Opinion of RAPT
Barclays gave a rating of “Equal Weight” to RAPT, setting the target price at $4 in the report published on May 10th of the current year.
RAPT Trading at 12.70% from the 50-Day Moving Average
After a stumble in the market that brought RAPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.96% of loss for the given period.
Volatility was left at 11.17%, however, over the last 30 days, the volatility rate increased by 13.47%, as shares sank -2.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.93% lower at present.
During the last 5 trading sessions, RAPT rose by +27.91%, which changed the moving average for the period of 200-days by -90.84% in comparison to the 20-day moving average, which settled at $1.85. In addition, RAPT Therapeutics Inc saw -91.15% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPT starting from Brockstedt Dirk G., who sale 898 shares at the price of $22.78 back on Jan 05 ’24. After this action, Brockstedt Dirk G. now owns 27,820 shares of RAPT Therapeutics Inc, valued at $20,456 using the latest closing price.
HO WILLIAM, the Chief Medical Officer of RAPT Therapeutics Inc, sale 2,500 shares at $21.68 during a trade that took place back on Dec 21 ’23, which means that HO WILLIAM is holding 15,020 shares at $54,200 based on the most recent closing price.
Stock Fundamentals for RAPT
Current profitability levels for the company are sitting at:
- -24.39 for the present operating margin
- 0.65 for the gross margin
The net margin for RAPT Therapeutics Inc stands at -22.77. The total capital return value is set at -1.15. Equity return is now at value -77.97, with -69.23 for asset returns.
Based on RAPT Therapeutics Inc (RAPT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -18.31. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -56.3.
Currently, EBITDA for the company is -125.85 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 8.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.14.
Conclusion
In conclusion, RAPT Therapeutics Inc (RAPT) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
